Get the Stockscreener App
4.10
18.16%
0.63
After Hours:
4.08
-0.02
-0.49%
Atai Life Sciences N V stock is traded at $4.10, with a volume of 15.84M.
It is up +18.16% in the last 24 hours and up +87.21% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
See More
Previous Close:
$3.47
Open:
$3.7
24h Volume:
15.84M
Relative Volume:
3.57
Market Cap:
$821.38M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-14.64
EPS:
-0.28
Net Cash Flow:
$-84.71M
1W Performance:
+9.63%
1M Performance:
+87.21%
6M Performance:
+164.52%
1Y Performance:
+164.52%
1-Day Range:
$3.655
$4.29
1-Week Range:
$3.06
$4.29
52-Week Range:
$1.03
$4.29
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
49 89 2153 9035
Address
WALLSTRASSE 16, BERLIN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
4.10 | 736.14M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Insider Monkey
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg
H.C. Wainwright raises atai Life Sciences stock price target to $15 on BPL-003 potential - Investing.com Australia
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Published on: 2025-07-30 03:07:04 - metal.it
What makes Atai Life Sciences N.V. stock price move sharplySwing Setup With Technical Confirmation Explained - metal.it
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Oppenheimer initiates atai Life Sciences stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates atai Life Sciences stock with Outperform rating - Investing.com
Published on: 2025-07-29 09:29:36 - metal.it
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI) - Seeking Alpha
ATAI Life Sciences Surges Amidst Market Uncertainty - StocksToTrade
Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News - Yahoo Finance
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - 富途牛牛
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 monthsUnstoppable trading performance - jammulinksnews.com
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday - Benzinga
What is Atai Life Sciences N.V. company’s growth strategyGet insider insights into market trends - jammulinksnews.com
What are Atai Life Sciences N.V. company’s key revenue driversExceptional stock performance - jammulinksnews.com
How volatile is Atai Life Sciences N.V. stock compared to the marketBuild wealth steadily with proven strategies - jammulinksnews.com
Why Atai Life Sciences N.V. stock attracts strong analyst attentionFree Access to Community - metal.it
Atai Life Sciences (ATAI) Shares Drop 12% After Schizophrenia Dr - GuruFocus
Atai Life Sciences shares fall 14.29% after-hours as schizophrenia drug fails to meet main endpoint. - AInvest
Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha
Published on: 2025-07-26 00:30:53 - PrintWeekIndia
ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint - Investing.com UK
Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint - Stock Titan
Canaccord Increases Atai Life Sciences (ATAI) PT, Keeps Buy Rating - Insider Monkey
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Is Atai Life Sciences N.V. a good long term investmentBreakout profit opportunities - PrintWeekIndia
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
What drives Atai Life Sciences N.V. stock priceExponential return rates - jammulinksnews.com
What analysts say about Atai Life Sciences N.V. stockMassive wealth growth - Autocar Professional
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - MSN
5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):